文献速递间质性肺疾病肺结节与肺癌

特发性肺纤维化患者的肺癌:欧洲多中心回顾性研究

Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe.
PubMed 文献 · Respirology · 2022-09-18

该研究覆盖欧洲七国2010至2021年,在3178例特发性肺纤维化(IPF)患者中识别324例肺癌,患病率10.2%。IPF诊断后10年末,存活IPF患者中26.6%被诊断肺癌。IPF合并肺癌患者全因死亡风险显著高于无肺癌者,抗纤维化治疗与手术与较低死亡风险相关。

要点

  • IPF患者中肺癌患病率约10.2%,10年累积诊断比例达26.6%。
  • IPF合并肺癌者全因死亡风险升高(HR 1.51)。
  • 抗纤维化治疗与较低全因死亡风险相关(HR 0.61)。

核心结论

  • 肺癌对IPF患者预后有显著不良影响。
  • 亟需制定IPF合并肺癌管理的共识声明。

研究设计与样本

  • 多中心回顾性研究,覆盖七个欧洲国家,时间2010年1月1日至2021年5月18日。
  • 共纳入3178例IPF患者,其中识别324例合并肺癌。

主要发现

  • IPF患者中肺癌患病率为10.2%。
  • IPF诊断后10年末,存活IPF患者中26.6%被诊断肺癌。
  • IPF合并肺癌患者全因死亡风险高于无肺癌IPF患者(HR 1.51,95%CI 1.22-1.86,p<0.0001)。
  • 单核细胞计数<0.60 K/μl者全因死亡风险低于≥0.95 K/μl者(HR 0.35,95%CI 0.17-0.72),0.60-<0.95 K/μl者亦较低(HR 0.42,95%CI 0.21-0.82),p=0.003。
  • 接受抗纤维化治疗的IPF合并肺癌患者全因死亡风险低于未接受者(HR 0.61,95%CI 0.42-0.87,p=0.006)。

临床怎么用

  • 对IPF患者应关注肺癌筛查与诊断。
  • IPF合并肺癌患者可考虑抗纤维化治疗以改善生存。
  • 技术上可手术者手术可能降低死亡风险,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: There remains a paucity of large databases for patients with idiopathic pulmonary fibrosis (IPF) and lung cancer. We aimed to create a European registry. METHODS: This was a multicentre, retrospective study across seven European countries between 1 January 2010 and 18 May 2021. RESULTS: We identified 324 patients with lung cancer among 3178 patients with IPF (prevalence = 10.2%). By the end of the 10 year-period following IPF diagnosis, 26.6% of alive patients with IPF had been diagnosed with lung cancer. Patients with IPF and lung cancer experienced increased risk of all-cause mortality than IPF patients without lung cancer (HR: 1.51, [95% CI: 1.22-1.86], p < 0.0001). All-cause mortality was significantly lower for patients with IPF and lung cancer with a monocyte count of either <0.60 or 0.60-<0.95 K/μl than patients with monocyte count ≥0.95 K/μl (HR [<0.60 vs. ≥0.95 K/μl]: 0.35, [95% CI: 0.17-0.72], HR [0.60-<0.95 vs. ≥0.95 K/μl]: 0.42, [95% CI: 0.21-0.82], p = 0.003). Patients with IPF and lung cancer that received antifibrotics presented with decreased all cause-mortality compared to those who did not receive antifibrotics (HR: 0.61, [95% CI: 0.42-0.87], p = 0.006). In the adjusted model, a significantly lower proportion of surgically treated patients with IPF and otherwise technically operable lung cancer experienced all-cause mortality compared to non-surgically treated patients (HR: 0.30 [95% CI: 0.11-0.86], p = 0.02). CONCLUSION: Lung cancer exerts a dramatic impact on patients with IPF. A consensus statement for the management of patients with IPF and lung cancer is sorely needed.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Karampitsakos T, Spagnolo P, Mogulkoc N, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe. Respirology. 2022. PMID: 36117239. doi:10.1111/resp.14363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。